Tazeen Ahmad
Stock Analyst at B of A Securities
(3.68)
# 763
Out of 5,072 analysts
213
Total ratings
50.32%
Success rate
6.26%
Average return
Main Sectors:
Stocks Rated by Tazeen Ahmad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $26 → $29 | $21.59 | +34.32% | 9 | Oct 20, 2025 | |
| SRRK Scholar Rock Holding | Initiates: Buy | $53 | $43.15 | +22.83% | 1 | Oct 9, 2025 | |
| PHVS Pharvaris | Upgrades: Neutral | $16 → $27 | $27.72 | -2.60% | 4 | Oct 9, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $453 → $520 | $445.12 | +16.82% | 5 | Sep 17, 2025 | |
| INCY Incyte | Maintains: Buy | $90 → $104 | $105.65 | -1.56% | 6 | Sep 4, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $227 → $230 | $210.01 | +9.52% | 11 | Sep 2, 2025 | |
| ARGX argenx SE | Maintains: Buy | $880 → $887 | $917.63 | -3.34% | 4 | Sep 2, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Underperform | $17 → $16 | $20.95 | -23.63% | 26 | Aug 21, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $82 → $76 | $86.25 | -11.88% | 19 | Aug 20, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $23 → $27 | $24.81 | +8.83% | 16 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $126 → $134 | $102.70 | +30.48% | 9 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $4.86 | +64.61% | 1 | Jul 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $73 → $95 | $107.42 | -11.56% | 9 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $7.10 | +111.27% | 12 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $22 → $4 | $10.44 | -61.67% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $1 → $0.8 | $0.89 | -9.74% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $27 | $19.40 | +39.18% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $28 | $12.42 | +125.44% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $73 → $70 | $96.09 | -27.15% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $40 | $10.99 | +263.97% | 4 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $184 → $179 | $151.58 | +18.09% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $14.10 | +56.03% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 → $3 | $6.09 | -50.74% | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $10.02 | +49.70% | 5 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $10 → $2 | $11.32 | -82.33% | 6 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $83 → $76 | $33.76 | +125.12% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $4.32 | +131.48% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2 → $6 | $1.10 | +445.45% | 2 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $12.14 | +23.56% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $2 | $4.33 | -53.81% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 | $1.67 | +259.28% | 4 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $75 → $15 | $16.45 | -8.79% | 3 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $390 → $60 | $188.54 | -68.18% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $5.28 | +203.03% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $173.46 | - | 4 | Apr 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $330 → $300 | $12.91 | +2,224.68% | 1 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $19 → $9 | $2.33 | +286.27% | 2 | Oct 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $48 | $23.81 | +101.60% | 6 | Oct 10, 2018 |
Apellis Pharmaceuticals
Oct 20, 2025
Maintains: Neutral
Price Target: $26 → $29
Current: $21.59
Upside: +34.32%
Scholar Rock Holding
Oct 9, 2025
Initiates: Buy
Price Target: $53
Current: $43.15
Upside: +22.83%
Pharvaris
Oct 9, 2025
Upgrades: Neutral
Price Target: $16 → $27
Current: $27.72
Upside: -2.60%
Alnylam Pharmaceuticals
Sep 17, 2025
Maintains: Buy
Price Target: $453 → $520
Current: $445.12
Upside: +16.82%
Incyte
Sep 4, 2025
Maintains: Buy
Price Target: $90 → $104
Current: $105.65
Upside: -1.56%
Ascendis Pharma
Sep 2, 2025
Maintains: Buy
Price Target: $227 → $230
Current: $210.01
Upside: +9.52%
argenx SE
Sep 2, 2025
Maintains: Buy
Price Target: $880 → $887
Current: $917.63
Upside: -3.34%
Sarepta Therapeutics
Aug 21, 2025
Maintains: Underperform
Price Target: $17 → $16
Current: $20.95
Upside: -23.63%
PTC Therapeutics
Aug 20, 2025
Maintains: Buy
Price Target: $82 → $76
Current: $86.25
Upside: -11.88%
ACADIA Pharmaceuticals
Aug 7, 2025
Maintains: Neutral
Price Target: $23 → $27
Current: $24.81
Upside: +8.83%
Aug 5, 2025
Maintains: Buy
Price Target: $126 → $134
Current: $102.70
Upside: +30.48%
Jul 11, 2025
Initiates: Buy
Price Target: $8
Current: $4.86
Upside: +64.61%
Jul 10, 2025
Maintains: Buy
Price Target: $73 → $95
Current: $107.42
Upside: -11.56%
Jul 1, 2025
Maintains: Buy
Price Target: $13 → $15
Current: $7.10
Upside: +111.27%
May 28, 2025
Downgrades: Underperform
Price Target: $22 → $4
Current: $10.44
Upside: -61.67%
May 19, 2025
Maintains: Underperform
Price Target: $1 → $0.8
Current: $0.89
Upside: -9.74%
May 19, 2025
Maintains: Buy
Price Target: $28 → $27
Current: $19.40
Upside: +39.18%
Mar 12, 2025
Maintains: Buy
Price Target: $54 → $28
Current: $12.42
Upside: +125.44%
Mar 10, 2025
Maintains: Buy
Price Target: $73 → $70
Current: $96.09
Upside: -27.15%
Mar 10, 2025
Maintains: Buy
Price Target: $42 → $40
Current: $10.99
Upside: +263.97%
Feb 7, 2025
Maintains: Buy
Price Target: $184 → $179
Current: $151.58
Upside: +18.09%
Dec 18, 2024
Initiates: Buy
Price Target: $22
Current: $14.10
Upside: +56.03%
Dec 16, 2024
Downgrades: Underperform
Price Target: $6 → $3
Current: $6.09
Upside: -50.74%
Oct 17, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $10.02
Upside: +49.70%
Sep 12, 2024
Downgrades: Underperform
Price Target: $10 → $2
Current: $11.32
Upside: -82.33%
May 31, 2024
Maintains: Buy
Price Target: $83 → $76
Current: $33.76
Upside: +125.12%
Mar 28, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $4.32
Upside: +131.48%
Mar 28, 2024
Maintains: Underperform
Price Target: $2 → $6
Current: $1.10
Upside: +445.45%
Feb 9, 2024
Initiates: Buy
Price Target: $15
Current: $12.14
Upside: +23.56%
Apr 24, 2023
Downgrades: Underperform
Price Target: $7 → $2
Current: $4.33
Upside: -53.81%
Nov 21, 2022
Downgrades: Underperform
Price Target: $6
Current: $1.67
Upside: +259.28%
Nov 17, 2022
Downgrades: Underperform
Price Target: $75 → $15
Current: $16.45
Upside: -8.79%
Jun 7, 2022
Downgrades: Neutral
Price Target: $390 → $60
Current: $188.54
Upside: -68.18%
Nov 2, 2021
Initiates: Neutral
Price Target: $16
Current: $5.28
Upside: +203.03%
Apr 25, 2019
Downgrades: Underperform
Price Target: n/a
Current: $173.46
Upside: -
Nov 2, 2018
Maintains: Buy
Price Target: $330 → $300
Current: $12.91
Upside: +2,224.68%
Oct 16, 2018
Downgrades: Underperform
Price Target: $19 → $9
Current: $2.33
Upside: +286.27%
Oct 10, 2018
Maintains: Neutral
Price Target: $46 → $48
Current: $23.81
Upside: +101.60%